{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:46:46Z","timestamp":1776934006113,"version":"3.51.2"},"reference-count":30,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The rising prevalence of cardiovascular (CV) risk factors in Portugal has translated into more than 35,000 annual deaths due to CV diseases. We performed a multicenter observational cohort study encompassing clinical activities performed between 2000 and 2019 to characterize the CV risk profile and LDL-C management of patients in every CV risk category using electronic health records of a regional population in Portugal. We analyzed data from 14 health centers and 1 central hospital in the north of Portugal of patients between 40 and 80 years that had at least 1 family medicine appointment at these institutions. Living patients were characterized on 31 December 2019. CV risk assessment was computed according to the 2019 ESC\/EAS Guidelines. Lipid-lowering therapy (LLT) and achievement of LDL-C targets were assessed. In total, the analysis included 78,459 patients. Patient proportions were 33%, 29%, 22%, and 17% for low, intermediate, high, and very high CV risk, respectively. Moderate-intensity statins were the most frequently used medication across all CV risk categories. High-intensity statins were used in 5% and 10% of high and very high CV risk patients, respectively. Ezetimibe was used in 6% and 10% of high and very high CV risk patients, respectively. LDL-C targets were achieved in 44%, 27%, 7%, and 3% of low, intermediate, high, and very high CV risk patients, respectively. For uncontrolled patients in the high and very high CV risk categories, a median LDL-C reduction of 44% and 53%, respectively, would be required to meet LDL-C targets. There are clear opportunities to optimize LDL-C management in routine clinical practice. The prescription of LLT according to CV risk represents an important missed treatment opportunity.<\/jats:p>","DOI":"10.3390\/jcm11226825","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:33:32Z","timestamp":1669005212000},"page":"6825","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data"],"prefix":"10.3390","volume":"11","author":[{"given":"Cristina","family":"Gavina","sequence":"first","affiliation":[{"name":"Cardiology Department, Pedro Hispano Hospital, Senhora da Hora, 4464-513 Matosinhos, Portugal"},{"name":"Department of Medicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"given":"Daniel Seabra","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Cardiology Department, Pedro Hispano Hospital, Senhora da Hora, 4464-513 Matosinhos, Portugal"},{"name":"Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7068-3132","authenticated-orcid":false,"given":"Marisa","family":"Pardal","sequence":"additional","affiliation":[{"name":"Novartis Farma, Produtos Farmac\u00eauticos S.A., 2740-255 Porto Salvo, Portugal"}]},{"given":"Marta","family":"Afonso-Silva","sequence":"additional","affiliation":[{"name":"Novartis Farma, Produtos Farmac\u00eauticos S.A., 2740-255 Porto Salvo, Portugal"}]},{"given":"Diana","family":"Grangeia","sequence":"additional","affiliation":[{"name":"Novartis Farma, Produtos Farmac\u00eauticos S.A., 2740-255 Porto Salvo, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-6297","authenticated-orcid":false,"given":"Ricardo Jorge","family":"Dinis-Oliveira","sequence":"additional","affiliation":[{"name":"MTG Research and Development Lab, 4200-604 Porto, Portugal"},{"name":"TOXRUN\u2013Toxicology Research Unit, Institute of Health Sciences, Advanced Polytechnic and University Cooperative (CESPU), CRL, 4585-116 Gandra, Portugal"},{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"given":"Francisco","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Hospital Lus\u00edadas, 1500-458 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-6000","authenticated-orcid":false,"given":"Tiago","family":"Taveira-Gomes","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, Portugal"},{"name":"MTG Research and Development Lab, 4200-604 Porto, Portugal"},{"name":"Center for Health Technology and Services Research (CINTESIS), 4200-450 Porto, Portugal"},{"name":"Faculty of Health Sciences, University Fernando Pessoa (FCS-UFP), 4249-004 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"ref_1","unstructured":"Bourbon, M., Alves, A.C., and Rato, Q. (2019). Preval\u00eancia de Fatores de Risco Cardiovascular Na Popula\u00e7\u00e3o Portuguesa, Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP)."},{"key":"ref_2","unstructured":"(2020). GBD 2019 Diseases and Injuries Collaborators Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gavina, C., Carvalho, D.S., Valente, F., Bernardo, F., Dinis-Oliveira, R.J., Santos-Ara\u00fajo, C., and Taveira-Gomes, T. (2022). 20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9050149"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.repc.2020.08.007","article-title":"Os Custos Da Aterosclerose Em Portugal","volume":"40","author":"Costa","year":"2021","journal-title":"Rev. Port. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ehjqcco\/qcaa060","article-title":"The Burden of Atherosclerosis in Portugal","volume":"7","author":"Costa","year":"2021","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","unstructured":"(2022, November 11). Administra\u00e7\u00e3o Central do Sistema de Sa\u00fade Operacionaliza\u00e7\u00e3o Da Contratualiza\u00e7\u00e3o Nos Cuidados de Sa\u00fade Prim\u00e1rios Para 2019. Available online: https:\/\/www.acss.min-saude.pt\/wp-content\/uploads\/2019\/02\/20190214_Operacionalizacao_CSP_2019_vf.pdf."},{"key":"ref_10","unstructured":"(2022, November 01). INE\u2014Plataforma de Divulga\u00e7\u00e3o Dos Censos 2021\u2014Resultados Provis\u00f3rios. Available online: https:\/\/www.ine.pt\/scripts\/db_censos_2021.html."},{"key":"ref_11","unstructured":"Portability, I., and Act, A. (2022, November 11). Guidance Regarding Methods for de-Identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act. Available online: https:\/\/privacysecurityacademy.com\/wp-content\/uploads\/2021\/03\/HHS-OCR-Guidance-on-De-Identification-of-PHI-2012.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Scientific Steering Committee on Behalf of the Simon Broome Register Group (1991). Risk of Fatal Coronary Heart Disease in Familial Hypercholesterolaemia. BMJ, 303, 893\u2013896.","DOI":"10.1136\/bmj.303.6807.893"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5001\/omj.2014.22","article-title":"Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising Their Suitability in the Omani Arab Population","volume":"29","author":"Banerjee","year":"2014","journal-title":"Oman Med. J."},{"key":"ref_14","unstructured":"(2022, November 11). OMOP CDM v5.3. Available online: https:\/\/ohdsi.github.io\/CommonDataModel\/cdm53.html."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-Analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12933-020-01164-8","article-title":"The DARWIN-T2D Network of the Italian Diabetes Society Cholesterol Lowering Therapies and Achievement of Targets for Primary and Secondary Cardiovascular Prevention in Type 2 Diabetes: Unmet Needs in a Large Population of Outpatients at Specialist Clinics","volume":"19","author":"Morieri","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.repc.2020.10.018","article-title":"Temporal Trends of Lipid Control in Very High Cardiovascular Risk Patients","volume":"40","author":"Nunes","year":"2021","journal-title":"Rev. Port. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an Extract from Red Yeast Chinese Rice, on Coronary Events in a Chinese Population with Previous Myocardial Infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2019.03.017","article-title":"Achievement of Low Density Lipoprotein (LDL) Cholesterol Targets in Primary and Secondary Prevention: Analysis of a Large Real Practice Database in Italy","volume":"285","author":"Presta","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","article-title":"Utilization of Lipid-Modifying Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients at High and Very-High Cardiovascular Risk: Real-World Evidence from Germany","volume":"268","author":"Dippel","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI Study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: A European Society of Cardiology Survey on the Lifestyle, Risk Factor and Therapeutic Management of Coronary Patients from 24 European Countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4093\/dmj.2020.0001","article-title":"Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction","volume":"44","author":"Kim","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Morieri, M.L., Pipino, C., and Doria, A. (2022). Pharmacogenetics of Cardiovascular Prevention in Diabetes: From Precision Medicine to Identification of Novel Targets. J. Pers. Med., 12.","DOI":"10.3390\/jpm12091402"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on Cardiovascular Risk of High Density Lipoprotein Targeted Drug Treatments Niacin, Fibrates, and CETP Inhibitors: Meta-Analysis of Randomised Controlled Trials Including 117,411 Patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and Design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) Study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6825\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:38Z","timestamp":1760145698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":30,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11226825"],"URL":"https:\/\/doi.org\/10.3390\/jcm11226825","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}